Measurement of the uncomplexed fraction of tissue inhibitor of metalloproteinases-1 in the prognostic evaluation of primary breast cancer patients

Molecular and Cellular Proteomics

Volumn 4, Issue 4, 2005, Pages 483-491

  Ørnbjerg Würtz, Sidse ^a   Christensen, Ib Jarle ^b   Schrohl, Anne Sofie ^a   Mouridsen, Henning ^c   Lademann, Ulrik ^a   Jensen, Vibeke ^a   Brünner, Nils ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b HVIDOVRE HOSPITAL   (Denmark)

^c Rigshospitalet   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

MATRIX METALLOPROTEINASE; TISSUE EXTRACT; TISSUE INHIBITOR OF METALLOPROTEINASE 1;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER GRADING; CANCER MORTALITY; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPOTHESIS; MAJOR CLINICAL STUDY; MULTIVARIATE ANALYSIS; OUTCOMES RESEARCH; POSTMENOPAUSE; PRACTICE GUIDELINE; PREMENOPAUSE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN ANALYSIS; PROTEIN LOCALIZATION; REGRESSION ANALYSIS; SCORING SYSTEM; TISSUE DISTRIBUTION; TUMOR VOLUME; VALIDATION PROCESS;

BREAST NEOPLASMS; DENMARK; DISEASE-FREE SURVIVAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; MULTIVARIATE ANALYSIS; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; REGRESSION ANALYSIS; REPRODUCIBILITY OF RESULTS; RETROSPECTIVE STUDIES; TISSUE INHIBITOR OF METALLOPROTEINASE-1;

EID: 17844394705     PISSN: 15359476     EISSN: None     Source Type: Journal    
DOI: 10.1074/mcp.M400209-MCP200     Document Type: Article

References (36)

1. Goldhirsch, A., Wood, W. C., Gelber, R. D., Coates, A. S., Thürlimann, B., and Senn, H. J. (2003) Meeting highlights: updated international expert consensus on the primary therapy of early breast cancer. J. Clin. Oncol. 21, 3357-3365
2. Early Breast Cancer Trialists' Collaborative Group (1998) Polychemotherapy for early breast cancer: an overview of the randomised trials. Lancet 352, 930-942
3. Early Breast Cancer Trialists' Collaborative Group (1998) Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 351, 1451-1467
4. Egeblad, M., and Werb, Z. (2002) New functions for the matrix metalloproteinases in cancer progression. Nature 2, 161-174
5. Toi, M., Ishigaki, S., and Tominaga, T. (1998) Metalloproteinases and tissue inhibitors of metalloproteinases. Breast Cancer Res. Treat. 52, 113-124
6. Nakopoulou, L., Panayotopoulou, E. G., Giannopoulou, I., Alexandrou, P., Katsarou, S., Athanassiadou, P., and Keramopoulos, A. (2002) Stromelysin-3 protein expression in invasive breast cancer: relation to proliferation, cell survival and patients' outcome. Mod. Pathol. 15, 1154-1161
7. Chenard, M. P., O'Siorain, L., Shering, S., Rouyer, N., Lutz, Y., Wolf, C., Basset, P., Belloco, J. P., and Duffy, M. J. (1998) High levels of stromelysin-3 correlate with poor prognosis in patients with breast carcinoma. Int. J. Cancer 69, 448-451
8. Talvensaari-Mattila, A., Pääkko, P., and Turpeenniemi-Hujanen, T. (2003) Matrix metalloproteinase-2 (MMP-2) is associated with survival in breast carcinoma. Br. J. Cancer 89, 1270-1275
9. Leppä, S., Saarto, T., Vehmanen, L., Blomqvist, C., and Elomaa, I. (2004) A high serum matrix metalloproteinase-2 level is associated with an adverse prognosis in node-positive breast carcinoma. Clin. Cancer Res. 10, 1057-1063
10. Ranuncolo, S. M., Armanasco, E., Cresta, C., Bal de Kier Joffe, E., and Puricelli, L. (2003) Plasma MMP-9 (92 kDa MMP) activity is useful in the follow-up and in the assessment of prognosis in breast cancer patients. Int. J. Cancer 106, 745-751
11. Lambert, E., Dassé, E., Haye, B., and Petitfrère, E. (2004) TIMPs as multi-facial proteins. Crit. Rev. Oncol./Hematol. 49, 187-198
12. Brew, K., Dinakarpandian, D., and Nagese, H. (2000) Tissue inhibitors of metalloproteinases: evolution, structure and function. Biochim. Biophys. Acta 1477, 267-283
13. Ree, A. H., Flørenes, V. A., Berg, J. P., Mælandsmo, G. M., Nesland, J. M., and Fodstad, Ø. (1997) High levels of messenger RNAs for tissue inhibitors of metalloproteinases (TIMP-1 and TIMP-2) in primary breast carcinomas are associated with development of distant metastases. Clin. Cancer Res. 3, 1623-1628
14. Nakopoulou, L., Giannopoulou, I., Stefanaki, K., Panayotopoulou, E., Tsirmpa, I., Alexandrou, P., Mavrommatis, J., Katsarou, S., and Davaris, P. (2002) Enhanced mRNA expression of tissue inhibitor of metalloproteinase-1 (TIMP-1) in breast carcinomas is correlated with adverse prognosis. J. Pathol. 197, 307-313
15. McCarthy, K., Maguire, T., McGreal, G., McDermott, E., O'Higgins, N., and Duffy, M. J. (1999) High levels of tissue inhibitor of metalloproteinase-1 predict poor outcome in patients with breast cancer. Int. J. Cancer (Pred. Oncol.) 84, 44-48
16. Schrohl, A. S., Christensen, I. J., Pedersen, A. N., Jensen, V., Mouridsen, H., Murphy, G., Foekens, J. A., Brünner, N., and Holten-Andersen, M. N. (2003) Tumor tissue concentrations of the proteinase inhibitors tissue inhibitor of metalloproteinases-1 (TIMP-1) and plasminogen activator inhibitor type-1 (PAI-1) are complementary in determining prognosis in primary breast cancer. Mol. Cell. Proteomics 2, 164-172
17. Schrohl, A. S., Holten-Andersen, M. N., Peters, H. A., Look, M. P., Meijer van Gelder, M. E., Klijn, J. G. M., Brünner, N., and Foekens, J. A. (2004) Tumor tissue levels of tissue inhibitor of metalloproteinase-1 as a prognostic marker in primary breast cancer. Clin. Cancer Res. 10, 2289-2298
18. Alexander, C. M., Howard, E. W., Bissell, M. J., and Werb, Z. (1996) Rescue of mammary epithelial cell apoptosis and entactin degradation by a tissue inhibitor of metalloproteinases-1 transgene. J. Cell Biol. 135, 1669-1677
19. Murphy, F. R., Issa, R., Zhou, X., Ratnarajah, S., Nagase, H., Arthur, M. J. P., Benyon, C., and Iredale, J. P. (2002) Inhibition of apoptosis of activated hepatic stellate cells by tissue inhibitor of metalloproteinase-1 is mediated via effects on matrix metalloproteinase, inhibition. J. Biol. Chem. 277, 11069-11076
20. Guedez, L., Stetler-Stevenson, W., Wolff, L., Wang, J., Fukushima, P., Mansoor, A., and Stetler-Stevenson, M. (1998) In vitro suppression of programmed cell death of B cells by tissue inhibitor of metalloproteinases-1. J. Clin. Investig. 102, 2002-2010
21. Li, G., Fridman, R., and Kim, H. R. C. (1999) Tissue inhibitor of metalloproteinase-1 inhibits apoptosis of human breast epithelial cells. Cancer Res. 59, 6267-6275
22. Hayakawa, T., Yamashita, K., Tanzawa, K., Uchijima, E., and Iwata, K. (1992) Growth-promoting activity of tissue inhibitor of metalloproteinases-1 (TIMP-1) for a wide range of cells. FEBS Lett. 298, 29-32
23. Lafleur, M. A., Handsley, M. M., Knäuper, V., Murphy, G., and Edwards, D. R. (2002) Endothelial tubulogenesis within fibrin gels specifically requires the activity of membrane-type-matrix metalloproteinases (MT-MMPs). J. Cell Sci. 115, 3427-3438
24. Cornelius, L. A., Nehring, L. C., Harding, E., Bolanowski, M., Welgus, H. G., Kobayashi, D. K., Pierce, R. A., and Shapiro, S. D. (1998) Matrix metalloproteinases generate angiostatin: effects on neovascularization. J. Immunol 161, 6845-6852
25. Fernandez, H. A., Kallenbach, K., Seghezzi, G., Grossi, E., Colvin, S., Schneider, R., Mignatti, P., and Galloway, A. (1999) Inhibition of endothelial cell migration by gene transfer of tissue inhibitor of metalloproteinases-1. J. Surg. Res. 82, 156-162
26. Duffy, M. J., and McCarthy, K. (1998) Matrix metalloproteinases in cancer: Prognostic markers and targets for therapy. Int. J. Onco. 12, 1343-1348
27. Polascilk, T. J., Oesterling, J. E., and Partin, A. W. (1999) Prostate specific antigen: a decade of discovery - what we have learned and where we are going. J. Urol. 162, 293-306
28. Cooksley, S., Hipkiss, J. B., Tickle, S. P., Holmes-Ievers, E., Docherty, A. J. P., Murphy, G., and Lawson, A. D. G. (1990) Immunoassays, for the detection of human collagenase, stromelysin, tissue inhibitor of metalloproteinases (TIMP) and enzyme-inhibitor complexes. Matrix 10, 285-291
29. Holten-Andersen, M. N., Christensen, I. J., Nielsen, H. J., Lilja, H., Murphy, G., Jensen, V., Brünner, N., and Piironen, T. (2002) Measurement of the noncomplexed free fraction of tissue inhibitor of metalloproteinases 1 in plasma by immunoassay. Clin. Chem. 48, 1305-1313
30. Holten-Andersen, M. N., Brünner, N., Maimonis, P., Jensen, V., Murphy, G., and Piironen, T. (2002) Characterization of monoclonal antibodies to tissue inhibitor of metalloproteinases-1. J. Clin. Ligand Assay 25, 87-90
31. Pedersen, A. N., Christensen, I. J., Stephens, R. W., Briand, P., Mouridsen, H. T., Danø, K., and Brünner, N. (2000) The complex between urokinase and its type-1 inhibitor in primary breast cancer: relation to survival. Cancer Res. 60, 6927-6934
32. Andersen, K. W., and Mouridsen, H. T. (1998) Danish Breast Cancer Cooperative Group (DBCG). A description of the register of the nation-wide program for primary breast cancer. Acta Oncol. 27, 627-647
33. Camiolo, S. M., Siuta, M. R., and Madeja, J. M. (1982) Improved medium for extraction of plasminogen activator from tissue. Prep. Biochem. 12, 297-305
34. Bradford, M. M. (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72, 248-254
35. Holten-Andersen, M. N., Murphy, G., Nielsen, H. J., Pedersen, A. N., Christensen, I. J., Høyer-Hansen, G., Brünner, N., and Stephens, R. W. (1999) Quantification of TIMP-1 in plasma from healthy blood donors and patients with advanced cancer. Br. J. Cancer 80, 495-503
36. Hembry, R. M., Murphy, G., and Reynolds, J. J. (1985) Immunolocalization of tissue inhibitor of metalloproteinases (TIMP) in human cells. Characterization and use of specific antiserum. J. Cell. Sci. 73, 105-119